LT3590332T - Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules - Google Patents

Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules

Info

Publication number
LT3590332T
LT3590332T LTEP19189533.3T LT19189533T LT3590332T LT 3590332 T LT3590332 T LT 3590332T LT 19189533 T LT19189533 T LT 19189533T LT 3590332 T LT3590332 T LT 3590332T
Authority
LT
Lithuania
Prior art keywords
mhc
molecules
genetically modified
major histocompatibility
histocompatibility complex
Prior art date
Application number
LTEP19189533.3T
Other languages
English (en)
Inventor
Lynn Macdonald
Andrew J. Murphy
Naxin Tu
Cagan Gurer
Vera VORONINA
Sean Stevens
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3590332T publication Critical patent/LT3590332T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
LTEP19189533.3T 2011-10-28 2012-10-26 Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules LT3590332T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552584P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
LT3590332T true LT3590332T (lt) 2022-08-10

Family

ID=47430036

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP12806199.1T LT2770822T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotos pelės, kuriose vyksta chimerinio didžiojo audinių suderinamumo komplekso (mhc) ii molekulių raiška
LTEP17171524.6T LT3272214T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
LTEP19189533.3T LT3590332T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP12806199.1T LT2770822T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotos pelės, kuriose vyksta chimerinio didžiojo audinių suderinamumo komplekso (mhc) ii molekulių raiška
LTEP17171524.6T LT3272214T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules

Country Status (25)

Country Link
US (6) US8847005B2 (lt)
EP (4) EP4052572A1 (lt)
JP (2) JP6285361B2 (lt)
KR (2) KR101926442B1 (lt)
CN (3) CN108707608A (lt)
AU (4) AU2012327205B2 (lt)
BR (1) BR112014009941B1 (lt)
CA (1) CA2852962C (lt)
CY (2) CY1119283T1 (lt)
DK (3) DK3272214T3 (lt)
ES (3) ES2640241T3 (lt)
HK (2) HK1196999A1 (lt)
HR (3) HRP20220616T1 (lt)
HU (2) HUE048511T2 (lt)
IL (3) IL231895B (lt)
IN (1) IN2014CN03892A (lt)
LT (3) LT2770822T (lt)
MX (1) MX355726B (lt)
PL (3) PL2770822T3 (lt)
PT (3) PT3590332T (lt)
RS (3) RS63220B1 (lt)
RU (1) RU2660564C2 (lt)
SG (3) SG10201510056SA (lt)
SI (3) SI3272214T1 (lt)
WO (1) WO2013063340A1 (lt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2016380A4 (en) 2006-04-26 2012-09-19 L 3 Comm Security & Detection MULTI-SOURCE MONITORING SYSTEMS
RU2660564C2 (ru) 2011-10-28 2018-07-06 Регенерон Фармасьютикалз, Инк. Генетически модифицированные мыши, экспрессирующие химерные молекулы главного комплекса гистосовместимости
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
MX358390B (es) 2011-10-28 2018-08-17 Regeneron Pharma Interleucina 6 y receptor de interleucina 6, humanizados.
SI2958938T1 (sl) * 2013-02-20 2019-08-30 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo humanizirane koreceptorje za celice T
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
RS57963B1 (sr) * 2013-02-22 2019-01-31 Regeneron Pharma Miševi koji eksprimiraju humanizovani glavni kompleks histokompatibilnosti
KR102309653B1 (ko) * 2013-03-11 2021-10-08 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자를 발현하는 유전자전이 마우스
CA2925564C (en) 2013-09-23 2023-03-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
EP3138397B1 (en) * 2013-10-15 2018-12-26 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
SI3129400T1 (sl) 2014-04-08 2020-07-31 Regeneron Pharmaceuticals, Inc. Živali, ki niso človek in imajo humanizirane receptorje FC-gama
NO2785538T3 (lt) 2014-05-07 2018-08-04
LT3157956T (lt) * 2014-06-19 2020-05-11 Regeneron Pharmaceuticals, Inc. Nepriklausantys žmonėms gyvūnai, turintys humanizuotą užprogramuotos ląstelių žūties 1 geną
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
PL3689140T3 (pl) 2014-11-24 2022-09-05 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
TR201903891T4 (tr) 2014-12-05 2019-04-22 Regeneron Pharma Bir insanlaştırılmış farklılaşma kümesi 47 genine sahip olan insan dışı hayvanlar.
WO2016164492A2 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
SI3376857T1 (sl) 2015-11-20 2021-09-30 Regeneron Pharmaceuticals, Inc. Nehumane živali, ki imajo humaniziran gen 3 za aktivacijo limfocitov
CN108779159B (zh) * 2016-02-04 2022-12-30 瑞泽恩制药公司 具有经改造的angptl8基因的非人动物
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
JP7053499B2 (ja) 2016-06-03 2022-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
AU2018375796A1 (en) 2017-11-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
RU2020131383A (ru) 2018-03-24 2022-04-26 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные животные, отличные от человека, для выработки терапевтических антител против комплексов пептид-mhc, способы их получения и варианты применения
MA52177A (fr) 2018-03-26 2021-02-17 Regeneron Pharma Rongeurs humanisés pour tester des agents thérapeutiques
AU2019308205A1 (en) 2018-07-16 2020-11-19 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
EP4048802A4 (en) * 2019-10-22 2023-11-22 The Trustees of Columbia University in the City of New York TRANSGENIC PIG, METHOD FOR THE PRODUCTION AND USE THEREOF AND METHOD FOR PRODUCING MICE OF THE HUMAN IMMUNE SYSTEM
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024064860A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
CA2246333A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
PT1017721E (pt) 1997-09-16 2009-05-07 Univ Oregon Health & Science Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
RU2236127C2 (ru) * 1998-03-30 2004-09-20 Рисерч Дивелопмент Фаундейшн Способ получения трансгенной мыши, не содержащей функциональный рецептор-1 рилизинг-фактора кортикотропина, способ идентификации агониста или антагониста рилизинг-фактора кортикотропина, урокортина или лиганда семейства рилизинг-фактора кортикотропина и способ скрининга соединений, которые являются аналогами или агонистами кортикостерона или кортикотропина, с использованием такой мыши
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7067308B1 (en) * 2000-03-28 2006-06-27 Bioagri Corporation Vector for genetically modifying non-human animals
WO2002000933A2 (en) 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005085438A1 (ja) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
ES2965212T3 (es) 2009-07-08 2024-04-11 Kymab Ltd Modelos de animales y moléculas terapéuticas
CN101695587B (zh) * 2009-10-21 2012-08-29 上海中山医疗科技发展公司 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法
JP2013538555A (ja) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
US9557323B2 (en) 2010-09-24 2017-01-31 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
RU2660564C2 (ru) 2011-10-28 2018-07-06 Регенерон Фармасьютикалз, Инк. Генетически модифицированные мыши, экспрессирующие химерные молекулы главного комплекса гистосовместимости
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SI2958938T1 (sl) 2013-02-20 2019-08-30 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo humanizirane koreceptorje za celice T
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
RS57963B1 (sr) 2013-02-22 2019-01-31 Regeneron Pharma Miševi koji eksprimiraju humanizovani glavni kompleks histokompatibilnosti
KR102309653B1 (ko) 2013-03-11 2021-10-08 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자를 발현하는 유전자전이 마우스
WO2016164492A2 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals

Also Published As

Publication number Publication date
US8847005B2 (en) 2014-09-30
IL243565A (en) 2017-10-31
RU2660564C2 (ru) 2018-07-06
HRP20200305T1 (hr) 2020-06-12
DK3272214T3 (da) 2020-03-02
PL2770822T3 (pl) 2017-11-30
PT3590332T (pt) 2022-05-27
DK3590332T3 (da) 2022-05-23
SG10201909638UA (en) 2019-11-28
HUE034374T2 (en) 2018-02-28
LT2770822T (lt) 2017-10-10
AU2016202317B2 (en) 2017-11-30
RS59997B1 (sr) 2020-04-30
CN108707608A (zh) 2018-10-26
HRP20171327T1 (hr) 2017-11-03
WO2013063340A1 (en) 2013-05-02
ES2774488T3 (es) 2020-07-21
IL260209B (en) 2019-12-31
MX2014004896A (es) 2014-09-12
EP2770822B9 (en) 2019-12-11
US20210195878A1 (en) 2021-07-01
AU2016202317A1 (en) 2016-05-05
AU2018201402C1 (en) 2021-05-06
US9585373B2 (en) 2017-03-07
RU2018115251A3 (lt) 2021-09-07
US20190239496A1 (en) 2019-08-08
EP2770822B1 (en) 2017-06-14
SI2770822T1 (sl) 2017-10-30
CN104039133B (zh) 2018-05-04
PL3590332T3 (pl) 2022-06-13
US20190239497A1 (en) 2019-08-08
BR112014009941A2 (pt) 2020-12-22
US10219493B2 (en) 2019-03-05
CN104039133A (zh) 2014-09-10
IL231895B (en) 2018-07-31
HK1196999A1 (en) 2015-01-02
RS63220B1 (sr) 2022-06-30
US10986822B2 (en) 2021-04-27
AU2018201402B2 (en) 2020-10-22
SG10201510056SA (en) 2016-01-28
RU2018115251A (ru) 2019-03-04
RU2014116577A (ru) 2015-12-10
SI3272214T1 (sl) 2020-04-30
PT3272214T (pt) 2020-03-04
ES2914374T3 (es) 2022-06-10
US20150040253A1 (en) 2015-02-05
BR112014009941B1 (pt) 2022-11-29
JP2018019700A (ja) 2018-02-08
CY1122700T1 (el) 2021-03-12
NZ623146A (en) 2016-06-24
CY1119283T1 (el) 2018-02-14
NZ717130A (en) 2018-07-27
KR102113108B1 (ko) 2020-05-20
SG11201400938UA (en) 2014-04-28
ES2640241T3 (es) 2017-11-02
KR101926442B1 (ko) 2018-12-12
IL231895A0 (en) 2014-05-28
EP4052572A1 (en) 2022-09-07
KR20140089558A (ko) 2014-07-15
EP3272214B1 (en) 2019-11-27
LT3272214T (lt) 2020-03-10
EP3590332B1 (en) 2022-02-23
PT2770822T (pt) 2017-09-18
AU2012327205B2 (en) 2016-01-14
SI3590332T1 (sl) 2022-07-29
IN2014CN03892A (lt) 2015-10-16
JP2014532411A (ja) 2014-12-08
CN108401986B (zh) 2021-09-21
CN108401986A (zh) 2018-08-17
HUE048511T2 (hu) 2020-07-28
DK2770822T3 (en) 2017-09-25
EP2770822A1 (en) 2014-09-03
CA2852962C (en) 2022-05-03
RS56330B1 (sr) 2017-12-29
PL3272214T3 (pl) 2020-06-29
US20130111616A1 (en) 2013-05-02
KR20180132970A (ko) 2018-12-12
AU2021200438B2 (en) 2023-11-02
US11219195B2 (en) 2022-01-11
MX355726B (es) 2018-04-27
JP6285361B2 (ja) 2018-02-28
JP6652529B2 (ja) 2020-02-26
EP3590332A1 (en) 2020-01-08
IL260209A (en) 2018-07-31
AU2012327205A1 (en) 2013-05-23
EP3272214A1 (en) 2018-01-24
HRP20220616T1 (hr) 2022-06-24
CA2852962A1 (en) 2013-05-02
US20170135329A1 (en) 2017-05-18
AU2018201402A1 (en) 2018-03-15
HK1250131A1 (zh) 2018-11-30
AU2021200438A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
HK1250131A1 (zh) 表達嵌合主要組織相容性複合物(mhc)ii類分子的基因修飾小鼠
IL261239A (en) Mice with genetic mhc alterations
IL232098B (en) Mice with genetic changes in the t-cell receptor
HK1212859A1 (zh) 表達嵌合的主要組織相容性複合物 類分子的轉基因小鼠
HK1213144A1 (zh) 表達嵌合主要組織相容性複合物 類分子的基因修飾小鼠